论文部分内容阅读
小诺霉素(MCR,曾译相模湾霉素,Sagamicin,)是一种新的氨基糖苷类抗生素,我们将它与庆大霉素(GM)比较,进行临床对照试验。242例各种细菌感染性疾病被随机顺序分配在两组中,A组162例用MCR治疗;B组80例用GM治疗作为对照。在这些病例中A组和B组各含有革蓝氏阴性菌感染126例和63例。无论是MCR,还是GM,剂量皆相同,成人都是肌注120mg,一日2次,而儿童日剂量为3～4mg/kg,疗程4～10天(少数超过10天),结果MCR的显效率为75.3％,而GM为66.3％,显示MCR的疗效较好.特别是对革蓝氏阴性菌感染疗效更好。试管内临床分离的各种细菌对MCR的抑菌试验也证明大多数革蓝氏阴性菌是敏感的(82.9％),显著地高于GM(74.4％)。本研究未发现MCR对听觉、心、肝、肾功能及血液电解质的影响。
The microtomycin (MCR), a new aminoglycoside antibiotic, is compared to gentamicin (GM) for clinical controlled trials. A total of 242 cases of various bacterial infections were randomly assigned to two groups, 162 in group A treated with MCR and 80 in group B treated with GM as control. In these cases, Group A and Group B contained 126 and 63 Gram-negative bacteria each. Whether MCR, or GM, the doses are the same, adults are intramuscular 120mg, 2 times a day, while the daily dose of 3 ~ 4mg / kg, the treatment of 4 to 10 days (a few more than 10 days), the results were significantly MCR The efficiency was 75.3% and the GM was 66.3%, which showed that the curative effect of MCR was better, especially for Gram-negative bacteria infection. Bacteriostasis tests of MCR by various bacteria isolated in vitro in vitro also demonstrated that most of the gram-negative bacteria were sensitive (82.9%), significantly higher than GM (74.4%). This study found no effect of MCR on hearing, heart, liver, kidney function and blood electrolytes.